CYP19A1 and breast carcinoma: Denysschen et al. [20] conducted an eight-week pre/post-test trial of a home-based exercise program (resistance exercises and self-selected aerobic exercise) among 26 breast cancer patients who were receiving an aromatase inhibitor.